CoreCap Advisors’s Viking Therapeutics VKTX Stock Holding History

CoreCap Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.33K	Hold	102	–	–	﹤0.01%	2356
2026 Q2	$3.98K	Hold	102	–	–	﹤0.01%	2346
2026 Q1	$3.32K	Buy	102 +50	+96%	+$1.61K	﹤0.01%	2290
2025 Q4	$1.83K	Hold	52	–	–	﹤0.01%	2494
2025 Q3	$1.37K	Buy	52 +15	+41%	+$447	﹤0.01%	2435
2025 Q2	$981	Buy	37 +8	+28%	+$211	﹤0.01%	2420
2025 Q1	$700	Sell	29 -6	-17%	-$190	﹤0.01%	2604
2024 Q4	$1.41K	Buy	35 +34	+3,400%	+$1.94K	﹤0.01%	2308
2024 Q3	$63	Hold	1	–	–	﹤0.01%	2572
2024 Q2	$53	Hold	1	–	–	﹤0.01%	1556
2024 Q1	$82	Buy	+1	New	+$44	﹤0.01%	2454

Other funds holding VKTX

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

NWMP

Noble Wealth Management PBC Greenwood Village, Colorado $223M AUM 7.64% 1-Year Est. Return

BFS

Burkett Financial Services Rock Hill, South Carolina $331M AUM 14.93% 1-Year Est. Return

GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return

Paladin Partners Hartland, Wisconsin $162M AUM 13.31% 1-Year Est. Return

WETS

Wealth Enhancement Trust Services Sioux Falls, South Dakota $937M AUM 18.56% 1-Year Est. Return

Planning Strategies Lancaster, Pennsylvania $169M AUM

CoreCap Advisors's VKTX Position: Q3 2026 in Review

CoreCap Advisors held its Viking Therapeutics (VKTX) position steady in Q3 2026 at 102 shares worth $3.33K. The position accounts for ﹤0.01% of the portfolio, ranked #2356.

CoreCap Advisors first reported a position in VKTX in Q1 2024 and has held it in 11 quarters since. The position peaked at $3.98K in Q2 2026. 11 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

CoreCap Advisors held 102 shares of Viking Therapeutics worth $3.33K as of Q3 2026.
CoreCap Advisors left its Viking Therapeutics share count unchanged in Q3 2026.
Viking Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2356 holding.
CoreCap Advisors first reported a position in Viking Therapeutics in Q1 2024 and has held it in 11 quarters since.
CoreCap Advisors's Viking Therapeutics position peaked at $3.98K in Q2 2026.
11 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.